BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Orient EuroPharm launches oral uterine fibroids drug in Hong Kong, Taiwan

September 2, 2015 | News | By BioSpectrum Bureau

Orient EuroPharm launches oral uterine fibroids drug in Hong Kong, Taiwan



Singapore: Orient EuroPharma has launched new oral uterine fibroids drug, ulipristal acetate, developed by French company Laboratoire HRA Pharma, in Hong Kong and Taiwan simultaneously.

Ulipristal acetate is used for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The new generation drug, launched in European markets such as the Great British, France, Germany, can effectively control bleeding, alleviate symptoms, facilitate the surgery, and prevent from causing side effect like hot flush which can usually be seen in conventional treatment.

Dr Tsang-Tang Hsieh, vice superintendent, Taipei Chang Gung Memorial Hospital, indicated bleeding is the most common symptom of uterine fibroids. The symptoms of uterine fibroids are related to the size as well as location of the fibroids. Fibroids that are located in the outer layer of the uterine tends to oppress bladder and large intestine, whereas those found in the inner layer of the uterine and close to the uterine cavity are particularly easy to cause bleeding.